Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jan 1997

Einspahr J G, Alberts D S, Gapstur S M, Bostick R M, Emerson S S, Gerner E W

Abstract excerpt

Surrogate end-point biomarkers (SEBs) have become widely used in short-term cancer chemoprevention trials in place of cancer end points. This paper discusses criteria relevant to the selection and validation of SEBs for colon cancer risk and the use of SEBs in colon cancer chemoprevention trials....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Mutation

Share to Polyamines

Share to Precancerous Conditions

Share to Reproducibility of Results

Share to Risk Factors

Source

Identifiers

PMID: 8993796

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-8993796-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.PMID 8993796Read ↗

Tissue markers of colon cancer risk.Semantic proximity Read ↗

Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention.Semantic proximity Read ↗

Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment.Semantic proximity Read ↗

Molecular and clinical risk markers in colon cancer trials.Semantic proximity Read ↗

Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.Semantic proximity Read ↗

Emerging diet-related surrogate end points for colorectal cancer: UK Food Standards Agency diet and colonic health workshop report.Semantic proximity Read ↗

Does butyrate protect from colorectal cancer?Semantic proximity Read ↗

Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.Semantic proximity Read ↗

Bile acids as carcinogens in the colon and at other sites in the gastrointestinal systemSemantic proximity Read ↗

Protective role of wheat bran fiber: data from marker trials.Semantic proximity Read ↗

Quantification of human intestinal gene expression profiles using exfoliated colonocytes: a pilot studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.